A world-first capsid bioengineering platform capable of optimizing the whole capsid structure to overcome the recurrent clinical challenges in gene therapy.
Naturally occurring AAV vectors did not evolve for therapeutic use. They transduce human tissues with low efficiency, which drives up therapeutic doses and increases both cost and safety concerns.
Unfortunately, research findings from animal models often fail to translate to humans, putting patients at risk and causing clinical trials to end prematurely.
Developing an optimal capsid for a specific therapeutic target is a complex bioengineering problem that needs to account for multiple factors such as tissue specificity, cell transduction efficiency, immunogenicity, production costs, and more.
The number of possible capsid variants are larger than the protons in the obserbable universe, which is intractable for traditional directed evolution approaches.
Our purpose-built AI models enable the screening of billions of variants through rapid in silico directed evolution.
Bioengineered capsids are selected for desired attributes on human-relevant models, de-risking clinical development.
Capsid design is focused on addressing specific diseases with true unmet medical needs.
We are using a first-principles approach to optimize the whole capsid structure to overcome recurrent clinical challenges simultaneously.
We generate clinically and commercially significant datasets for each capsid variant selected using our patent-pending functional transduction platform.
We are specialists in structural biology, bioinformatics, vectorology, artificial intelligence, entrepreneurship, and have first-hand experience with the impact of genetic disorders.
We are strategically aligned with scientific, clinical and commercial experts to de-risk research-and-development and corporate execution.
